Biomarker · Hormone receptor

Androgen receptor (AR)

Androgen receptor expression or alteration assessed by immunohistochemistry or sequencing; the therapeutic target of androgen-deprivation and AR-pathway inhibitors in prostate cancer and a subtyping marker in breast cancer.

CI-BIO-00000036AR graph →NCIt C94297

Also calledAR · AR-positive · androgen receptor expression

Derived

Associated cancers (3)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Prostate Neoplasm	6	6	—	—	0 / 5 / 0 / 1 / 0
Malignant Breast Neoplasm	1	1	—	—	0 / 0 / 0 / 1 / 0
Prostate Carcinoma	1	1	—	—	0 / 0 / 0 / 1 / 0

Derived

Drugs with predictive evidence (8)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
EnzalutamideSmall Molecule	5	—	5	B	0 / 5	Malignant Prostate Neoplasm
AbirateroneSmall Molecule	4	—	4	B	0 / 4	Malignant Prostate Neoplasm
BicalutamideSmall Molecule

Curated evidence

Predictive evidence items (8)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
AR OVEREXPRESSION1
Dactolisib

Regulatory

Approvals mentioning the linked drugs (98)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpdRegulatory

Clinical trials

Active trials (92)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 42 recruiting · 18 active phase 3 · 351 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–50 of 92 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02489318	A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC(TITAN)	active not recruiting

Literature

Linked publications (12)

Publications linked to the scope gene(s) through PubMed entity edges; 25 per page, newest first.

pubmedPublishedShowing 1–12 of 12 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Integrative clinical genomics of advanced prostate cancer.
· Cell · 2015 · PMID 26000489 · validated civic_curation pubmed
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
· J Clin Oncol · 2019 · PMID 30865549 · validated civic_curation pubmed
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
· JAMA Oncol · 2016 · PMID 27262168 · validated civic_curation pubmed
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.

AR AR-V74
Abiraterone + EnzalutamideSubstitutes	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	4	accepted	EID9547 This multicenter clinical trial study (PROPHECY) enrolled 118 patients with metastatic castration-resistant prostate cancers (CRPC) on Abiraterone or Enzalutamide treatment. The Johns Hopkins Universi… (full text at CIViC) PMID 30865549 · Armstrong et al., 2019 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	4	accepted	EID12463 A cross-sectional cohort study was performed in 161 men with metastatic prostate cancer undergoing a change in treatment to determine if pre-therapy AR-V7 nuclear protein expression in circulating tum… (full text at CIViC) PMID 27262168 · Scher et al., 2016 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	4	accepted	EID12464 A blinded, multi-institutional cohort study was performed in 142 men with metastatic, castration-resistant prostate cancer to determine if pre-therapy nuclear-localized expression of AR-V7 protein in … (full text at CIViC) PMID 29955787 · Scher et al., 2018 · Open in CIViC	civic
Abiraterone + EnzalutamideSubstitutes	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	3	accepted	EID863 This prospective study enrolled 31 Enzalutamide-treated (group 1) and 31 Abiraterone-treated (group 2) patients with metastatic castration-resistant prostate cancers (CRPC). AR-V7 variant was detected… (full text at CIViC) PMID 25184630 · Antonarakis et al., 2014 · Open in CIViC	civic

AR AR-V74

Abiraterone + EnzalutamideSubstitutes

Malignant Prostate Neoplasm

Predictive

Supports Resistance

accepted

EID9547

This multicenter clinical trial study (PROPHECY) enrolled 118 patients with metastatic castration-resistant prostate cancers (CRPC) on Abiraterone or Enzalutamide treatment. The Johns Hopkins Universi… (full text at CIViC)

PMID 30865549 · Armstrong et al., 2019 · Open in CIViC

civic

〃

Malignant Prostate Neoplasm

Predictive

Supports Resistance

accepted

EID12463

A cross-sectional cohort study was performed in 161 men with metastatic prostate cancer undergoing a change in treatment to determine if pre-therapy AR-V7 nuclear protein expression in circulating tum… (full text at CIViC)

PMID 27262168 · Scher et al., 2016 · Open in CIViC

civic

〃

Malignant Prostate Neoplasm

Predictive

Supports Resistance

accepted

EID12464

A blinded, multi-institutional cohort study was performed in 142 men with metastatic, castration-resistant prostate cancer to determine if pre-therapy nuclear-localized expression of AR-V7 protein in … (full text at CIViC)

PMID 29955787 · Scher et al., 2018 · Open in CIViC

civic

Abiraterone + EnzalutamideSubstitutes

Malignant Prostate Neoplasm

Predictive

Supports Resistance

accepted

EID863

This prospective study enrolled 31 Enzalutamide-treated (group 1) and 31 Abiraterone-treated (group 2) patients with metastatic castration-resistant prostate cancers (CRPC). AR-V7 variant was detected… (full text at CIViC)

PMID 25184630 · Antonarakis et al., 2014 · Open in CIViC

civic

AR Mutation1
Bicalutamide + Cyproterone Acetate + Flutamide + NilutamideSubstitutes	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	4	accepted	EID1521 In a study of 150 patients with metastatic castration resistant prostate cancer (mCRPC), 71.3% of cases (n=107) harbored androgen receptor (AR) pathway aberrations. Within the AR mutation cohort, 78… (full text at CIViC) PMID 26000489 · Robinson et al., 2015 · Open in CIViC	civic

AR Mutation1

Bicalutamide + Cyproterone Acetate + Flutamide + NilutamideSubstitutes

Malignant Prostate Neoplasm

Predictive

Supports Resistance

accepted

EID1521

In a study of 150 patients with metastatic castration resistant prostate cancer (mCRPC), 71.3% of cases (n=107) harbored androgen receptor (AR) pathway aberrations. Within the AR mutation cohort, 78… (full text at CIViC)

PMID 26000489 · Robinson et al., 2015 · Open in CIViC

civic

AR F877L1
Apalutamide + EnzalutamideSubstitutes	Malignant Prostate Neoplasm	Predictive	D	Supports Resistance	4	accepted	EID447 Mutations F876L in the ligand binding domain of the androgen receptor confered resistance to enzalutamide and ARN-509, causing these compounds to function as partial agonists in two prostate cancer ce… (full text at CIViC) PMID 23779130 · Joseph et al., 2013 · Open in CIViC	civic

AR F877L1

Apalutamide + EnzalutamideSubstitutes

Malignant Prostate Neoplasm

Predictive

Supports Resistance

accepted

EID447

Mutations F876L in the ligand binding domain of the androgen receptor confered resistance to enzalutamide and ARN-509, causing these compounds to function as partial agonists in two prostate cancer ce… (full text at CIViC)

PMID 23779130 · Joseph et al., 2013 · Open in CIViC

civic

AR W7421
Bicalutamide	Prostate Carcinoma	Predictive	D	Supports Resistance	4	accepted	EID448 LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion. PMID 12517791 · Hara et al., 2003 · Open in CIViC	civic

AR W7421

Bicalutamide

Prostate Carcinoma

Predictive

Supports Resistance

accepted

EID448

LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion.

PMID 12517791 · Hara et al., 2003 · Open in CIViC

civic

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Apalutamide	CA Health Canada	—	Marketed in Canada as ERLEADA (DIN 02540185) under ATC L02BB05 APALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 1, 2023	health-canada-dpd
Apalutamide	CA Health Canada	—	Marketed in Canada as ERLEADA (DIN 02478374) under ATC L02BB05 APALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 27, 2018	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as BICALUTAMIDE (DIN 02519178) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 28, 2022	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as VAN-BICALUTAMIDE (DIN 02428709) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 7, 2019	Jun 22, 2015	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as RAN-BICALUTAMIDE (DIN 02371324) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 23, 2022	Sep 7, 2012	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as BICALUTAMIDE (DIN 02382423) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jan 22, 2020	Jun 10, 2012	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as AVA-BICALUTAMIDE (DIN 02360993) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 21, 2014	Nov 23, 2011	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as JAMP BICALUTAMIDE (DIN 02357216) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 21, 2010	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as ACH-BICALUTAMIDE (DIN 02325985) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 5, 2010	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as BICALUTAMIDE (DIN 02325233) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jun 20, 2014	Jun 22, 2009	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as PRO-BICALUTAMIDE (DIN 02311038) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 9, 2008	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as DOM-BICALUTAMIDE (DIN 02281139) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 9, 2025	Apr 16, 2008	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as MYLAN-BICALUTAMIDE (DIN 02302403) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jan 9, 2017	Dec 20, 2007	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as APO-BICALUTAMIDE (DIN 02296063) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince May 14, 2023	Nov 5, 2007	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as PHL-BICALUTAMIDE (DIN 02281163) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 21, 2006	Jul 21, 2006	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as RATIO-BICALUTAMIDE (DIN 02277700) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 19, 2014	Mar 13, 2006	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as TEVA-BICALUTAMIDE (DIN 02270226) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 10, 2006	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as PMS-BICALUTAMIDE (DIN 02275589) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 8, 2006	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as SANDOZ BICALUTAMIDE (DIN 02276089) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 1, 2019	Feb 8, 2006	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as ACT BICALUTAMIDE (DIN 02274337) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 11, 2018	Feb 7, 2006	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as CASODEX (DIN 02184478) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Mar 7, 2025	Dec 31, 1996	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as NTP-BICALUTAMIDE (DIN 02358557) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Aug 6, 2015	—	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as NU-BICALUTAMIDE (DIN 02336545) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled (Unreturned Annual)since Mar 28, 2018	—	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as NRA-BICALUTAMIDE (DIN 02565919) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as MED-BICALUTAMIDE (DIN 02407531) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as AG-BICALUTAMIDE (DIN 02374412) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 14, 2026	—	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as ACCEL-BICALUTAMIDE TABLETS USP (DIN 02400731) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince May 19, 2017	—	health-canada-dpd
Bicalutamide	CA Health Canada	—	Marketed in Canada as BICALUTAMIDE TABLETS (DIN 02360098) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Mar 10, 2023	—	health-canada-dpd
Enzalutamide	CA Health Canada	—	Marketed in Canada as AURO-ENZALUTAMIDE (DIN 02494736) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 30, 2026	health-canada-dpd
Enzalutamide	CA Health Canada	—	Marketed in Canada as REDDY-ENZALUTAMIDE (DIN 02558424) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 30, 2026	health-canada-dpd
Enzalutamide	CA Health Canada	—	Marketed in Canada as APO-ENZALUTAMIDE (DIN 02562677) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 30, 2026	health-canada-dpd
Enzalutamide	CA Health Canada	—	Marketed in Canada as JAMP ENZALUTAMIDE (DIN 02515229) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 20, 2026	health-canada-dpd
Enzalutamide	CA Health Canada	—	Marketed in Canada as XTANDI (DIN 02407329) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 7, 2013	health-canada-dpd
Enzalutamide	CA Health Canada	—	Marketed in Canada as PRO-ENZALUTAMIDE (DIN 02569124) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Enzalutamide	CA Health Canada	—	Marketed in Canada as PMS-ENZALUTAMIDE (DIN 02570831) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Flutamide	CA Health Canada	—	Marketed in Canada as FLUTAMIDE-250 (DIN 02239388) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 23, 2009	Feb 22, 1999	health-canada-dpd
Flutamide	CA Health Canada	—	Marketed in Canada as FLUTAMIDE (DIN 02239045) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 25, 2016	Dec 1, 1998	health-canada-dpd
Flutamide	CA Health Canada	—	Marketed in Canada as FLUTAMIDE (DIN 02238560) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 8, 1998	health-canada-dpd
Flutamide	CA Health Canada	—	Marketed in Canada as FLUTAMIDE (DIN 02230875) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 28, 2016	Oct 31, 1997	health-canada-dpd
Flutamide	CA Health Canada	—	Marketed in Canada as PMS-FLUTAMIDE (DIN 02230104) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 4, 2025	Feb 21, 1997	health-canada-dpd
Flutamide	CA Health Canada	—	Marketed in Canada as TEVA-FLUTAMIDE (DIN 02230089) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 30, 2018	Jan 16, 1997	health-canada-dpd
Flutamide	CA Health Canada	—	Marketed in Canada as FLUTAMIDE (DIN 02059673) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 31, 2014	Dec 31, 1996	health-canada-dpd
Flutamide	CA Health Canada	—	Marketed in Canada as EUFLEX (DIN 00637726) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jun 1, 2015	Dec 31, 1984	health-canada-dpd
Flutamide	CA Health Canada	—	Marketed in Canada as PENTA-FLUTAMIDE (DIN 02233019) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled (Unreturned Annual)since Apr 5, 2018	—	health-canada-dpd
Flutamide	CA Health Canada	—	Marketed in Canada as NU-FLUTAMIDE TABLETS (DIN 02239082) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled (Unreturned Annual)since Mar 28, 2018	—	health-canada-dpd
Flutamide	CA Health Canada	—	Marketed in Canada as DOM-FLUTAMIDE (DIN 02230524) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Mar 26, 2025	—	health-canada-dpd
Nilutamide	CA Health Canada	—	Marketed in Canada as ANANDRON (DIN 02221861) under ATC L02BB02 NILUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Aug 3, 2024	Aug 20, 1997	health-canada-dpd
Nilutamide	CA Health Canada	—	Marketed in Canada as ANANDRON - TAB 100MG (DIN 02221888) under ATC L02BB02 NILUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 22, 2003	Aug 20, 1997	health-canada-dpd
Nilutamide	CA Health Canada	—	Marketed in Canada as ANANDRON TAB 50MG (DIN 01989642) under ATC L02BB02 NILUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 11, 1999	Dec 31, 1994	health-canada-dpd
Nilutamide	CA Health Canada	—	Marketed in Canada as ANANDRON TAB 100MG (DIN 00863904) under ATC L02BB02 NILUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 9, 1996	Dec 31, 1992	health-canada-dpd

Drug

Jurisdiction · authority

Cancer

Indication

Status

Approval date

Source

Apalutamide

CA Health Canada

—

Marketed in Canada as ERLEADA (DIN 02540185) under ATC L02BB05 APALUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.

approvedsource: Marketed

Nov 1, 2023